RxDoctor Payments Data

Lawrence Beck, MD

Neurology · Stratford, CTNPI 1992731889

Payments from drug & device makers

$12,723in general payments, 2019–2025

Across 702 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$2K
  • Genentech USA, Inc.$1K
  • UCB, Inc.$875
  • Biogen$796
  • SK Life Science, Inc.$682
  • plus $6K from 37 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$12,675100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,723 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$71,091
Medicare patients
258
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin14$145,549
Avonex (4 Pack)Interferon Beta-1a13$124,714
Kesimpta PenOfatumumab12$102,584
NamzaricMemantine Hcl/Donepezil Hcl24$36,956
RytaryCarbidopa/Levodopa16$31,685
Emgality PenGalcanezumab-Gnlm13$11,683
Carbidopa-LevodopaCarbidopa/Levodopa145$3,999
Carbamazepine ErCarbamazepine17$3,269
Gabapentin127$3,072
Levetiracetam107$2,728
Donepezil Hcl182$2,603
Lacosamide12$1,382
Propranolol Hcl ErPropranolol Hcl17$1,346
Phenytoin Sodium Extended27$988
Oxcarbazepine19$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$796$124,71413 claims
AbbVieNamzaric$2,165$36,95624 claims
Amneal Pharmaceuticals LLCRytary$318$31,68516 claims
Upsher-smith Laboratories LLCTopiramate$63$20915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.

Other neurology in Stratford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →